Study assessing symptoms of anxiety, depression and sleep quality disturbances in post-Covid-19 Mucormycosis patients admitted for in-patient treatment admitted at a tertiary care hospital

BACKGROUND: Mucormycosis (previously : zygomycosis) is a rare and serious fungal infection caused by a group of molds called mucormycetes. There are five major clinical forms of Mucormycosis; gastrointestinal, disseminated, rhinocerebral , cutaneous and pulmonary, of which the latter 3 are the most common.There have been no studies conducted on the association of anxiety and depression with Mucormycosis. MATERIALS AND METHODS : 50 sample size. Conducted in the special Mucormycosis ward at DY Patil Hospital. Scales used were HADS and GSQS. Assessment done on Day5 and Day15 of admission. RESULTS: 50 post-Covid-19 Mucormycosis patients were analysed. 31 patients were males, whereas 19 patients were females. The age group was 18-70.Out of the 50 patients, 32 had Cutaneous type of Mucormycosis; 15 had Pulmonary type of Mucormycosis and 3 had Rhinocerebral type of Mucormycosis. HADS Score was significantly higher on Day 15 (21.02 ± 8.35; P = 0.0000) as compared to Day 5 (17.0 ± 7.69; P = 0.0000) in all patients. GSQS Score was significantly higher on Day 15 (7.10 ± 3.04; P = 0.0000) as compared to Day 5 (4.34 ± 2.80; P = 0.0000) in all patients. CONCLUSION: Anxiety and Depressive symptoms , along with sleep quality impairment was observed in patients of post-Covid-19 Mucormycosis.